Paclitaxel
Description
Type: small molecule
Groups: approved
Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Accession Number: DB01229 ( APRD00259, DB05261, DB05927)
Description: Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]
Structure:
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Abraxane | injection, powder, lyophilized, for suspension | 100 mg/20mL | intravenous | 10-02-2005 | US | |
Abraxane for Injectable Suspension | powder for suspension | 100 mg | intravenous | 31-08-2006 | Canada | |
Aj-paclitaxel | solution | 6 mg | intravenous | 01-01-1970 | Canada | |
Paclitaxel | injection | 6 mg/mL | intravenous | 11-07-2013 | US | |
Paclitaxel | injection | 6 mg/mL | intravenous | 11-07-2013 | US | |
Paclitaxel | injection | 6 mg/mL | intravenous | 11-07-2013 | US | |
Paclitaxel | liquid | 6 mg | intravenous | 01-01-1970 | Canada | |
Paclitaxel for Injection | solution | 6 mg | intravenous | 01-01-1970 | Canada | |
Paclitaxel for Injection | solution | 6 mg | intravenous | 31-10-2001 | Canada | |
Paclitaxel for Injection | solution | 6 mg | intravenous | 17-12-2007 | Canada | |
Paclitaxel for Injection USP | solution | 6 mg | intravenous | 22-02-2011 | Canada | |
Paclitaxel Injection | liquid | 6 mg | intravenous | 01-01-1970 | Canada | |
Paclitaxel Injection | liquid | 6 mg | intravenous | 24-10-1997 | 06-12-2005 | Canada |
Paclitaxel Injection USP | solution | 6 mg | intravenous | 02-07-2014 | Canada | |
Paclitaxel Injection USP | solution | 6 mg | intravenous | 31-03-2015 | Canada | |
Paclitaxel Injection, USP | solution | 6 mg | intravenous | 01-01-1970 | Canada | |
Paxene | liquid | 6 mg | intravenous | 01-01-1970 | Canada | |
Taxol | solution | 6 mg | intravenous | 31-12-1993 | 20-07-2012 | Canada |
Teva-paclitaxel for Injection | liquid | 6 mg | intravenous | 01-01-1970 | Canada |
Generic Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Apo-paclitaxel Injectable | solution | 6 mg | intravenous | 07-02-2005 | Canada | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 20-03-2009 | US | |
Paclitaxel | injection | 300 mg/50mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection | 100 mg/16.7mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection, solution, concentrate | 6 mg/mL | intravenous | 03-11-2009 | US | |
Paclitaxel | injection, solution, concentrate | 6 mg/mL | intravenous | 24-09-2008 | US | |
Paclitaxel | injection, solution, concentrate | 6 mg/mL | intravenous | 23-10-2008 | US | |
Paclitaxel | injection, solution, concentrate | 6 mg/mL | intravenous | 16-09-2009 | US | |
Paclitaxel | injection | 30 mg/5mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection | 100 mg/16.7mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection | 300 mg/50mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection | 30 mg/5mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 27-09-2011 | US | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 05-01-2015 | US | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 02-01-2008 | US | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 08-05-2002 | US |
Over the Counter Products: Not Available
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Abraxane | injection, powder, lyophilized, for suspension | 100 mg/20mL | intravenous | 10-02-2005 | US | |
Abraxane for Injectable Suspension | powder for suspension | 100 mg | intravenous | 31-08-2006 | Canada | |
Aj-paclitaxel | solution | 6 mg | intravenous | 01-01-1970 | Canada | |
Paclitaxel | injection | 6 mg/mL | intravenous | 11-07-2013 | US | |
Paclitaxel | injection | 6 mg/mL | intravenous | 11-07-2013 | US | |
Paclitaxel | injection | 6 mg/mL | intravenous | 11-07-2013 | US | |
Paclitaxel | liquid | 6 mg | intravenous | 01-01-1970 | Canada | |
Paclitaxel for Injection | solution | 6 mg | intravenous | 01-01-1970 | Canada | |
Paclitaxel for Injection | solution | 6 mg | intravenous | 31-10-2001 | Canada | |
Paclitaxel for Injection | solution | 6 mg | intravenous | 17-12-2007 | Canada | |
Paclitaxel for Injection USP | solution | 6 mg | intravenous | 22-02-2011 | Canada | |
Paclitaxel Injection | liquid | 6 mg | intravenous | 01-01-1970 | Canada | |
Paclitaxel Injection | liquid | 6 mg | intravenous | 24-10-1997 | 06-12-2005 | Canada |
Paclitaxel Injection USP | solution | 6 mg | intravenous | 02-07-2014 | Canada | |
Paclitaxel Injection USP | solution | 6 mg | intravenous | 31-03-2015 | Canada | |
Paclitaxel Injection, USP | solution | 6 mg | intravenous | 01-01-1970 | Canada | |
Paxene | liquid | 6 mg | intravenous | 01-01-1970 | Canada | |
Taxol | solution | 6 mg | intravenous | 31-12-1993 | 20-07-2012 | Canada |
Teva-paclitaxel for Injection | liquid | 6 mg | intravenous | 01-01-1970 | Canada |
Generic Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Apo-paclitaxel Injectable | solution | 6 mg | intravenous | 07-02-2005 | Canada | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 20-03-2009 | US | |
Paclitaxel | injection | 300 mg/50mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection | 100 mg/16.7mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection, solution, concentrate | 6 mg/mL | intravenous | 03-11-2009 | US | |
Paclitaxel | injection, solution, concentrate | 6 mg/mL | intravenous | 24-09-2008 | US | |
Paclitaxel | injection, solution, concentrate | 6 mg/mL | intravenous | 23-10-2008 | US | |
Paclitaxel | injection, solution, concentrate | 6 mg/mL | intravenous | 16-09-2009 | US | |
Paclitaxel | injection | 30 mg/5mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection | 100 mg/16.7mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection | 300 mg/50mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection | 30 mg/5mL | intravenous | 30-09-2011 | US | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 27-09-2011 | US | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 05-01-2015 | US | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 02-01-2008 | US | |
Paclitaxel | injection, solution | 6 mg/mL | intravenous | 08-05-2002 | US |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
Brand Name | Ingredients |
---|---|
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Abraxane | Paclitaxel |
Paclitaxel for Injection | Paclitaxel |
Apo-paclitaxel Injectable | Paclitaxel |
Abraxane for Injectable Suspension | Paclitaxel |
Paclitaxel for Injection | Paclitaxel |
Paclitaxel for Injection USP | Paclitaxel |
Paclitaxel Injection USP | Paclitaxel |
Paclitaxel Injection USP | Paclitaxel |
Taxol | Paclitaxel |
Paclitaxel Injection | Paclitaxel |
Paclitaxel Injection | Paclitaxel |
Paxene | Paclitaxel |
Paclitaxel for Injection | Paclitaxel |
Paclitaxel Injection, USP | Paclitaxel |
Paclitaxel | Paclitaxel |
Teva-paclitaxel for Injection | Paclitaxel |
Aj-paclitaxel | Paclitaxel |
Brand Name | Ingredients |
---|---|
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Paclitaxel | Paclitaxel |
Abraxane | Paclitaxel |
Paclitaxel for Injection | Paclitaxel |
Apo-paclitaxel Injectable | Paclitaxel |
Abraxane for Injectable Suspension | Paclitaxel |
Paclitaxel for Injection | Paclitaxel |
Paclitaxel for Injection USP | Paclitaxel |
Paclitaxel Injection USP | Paclitaxel |
Paclitaxel Injection USP | Paclitaxel |
Taxol | Paclitaxel |
Paclitaxel Injection | Paclitaxel |
Paclitaxel Injection | Paclitaxel |
Paxene | Paclitaxel |
Paclitaxel for Injection | Paclitaxel |
Paclitaxel Injection, USP | Paclitaxel |
Paclitaxel | Paclitaxel |
Teva-paclitaxel for Injection | Paclitaxel |
Aj-paclitaxel | Paclitaxel |
Categories
- Antineoplastic Agents, Phytogenic
- Tubulin Modulators
- Taxane Derivatives
Pharmacology
Pharmacodynamics: Not Available
Mechanism of action: Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.
Absorption: When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ng•h/mL.
Volume of distribution:
- 227 to 688 L/m^2 [apparent volume of distribution at steady-state, 24 hour infusion]
Protein binding: 89%-98% bound to plasma protein. The presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.
Metabolism: Not Available
Route of elimination: In 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine.
Half life: When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.
Clearance: Not Available
Toxicity: Rat (ipr) LD50=32530 µg/kg. Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Overdoses in pediatric patients may be associated with acute ethanol toxicity.
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
- Not Available
Packagers:
- Abraxis BioScience Inc.
- Accord Healthcare
- APP Pharmaceuticals
- Barr Pharmaceuticals
- Bedford Labs
- Ben Venue Laboratories Inc.
- Bristol-Myers Squibb Co.
- Ebewe Pharma
- Ethex Corp.
- Fresenius Kabi AB
- Hospira Inc.
- Intas Pharmaceuticals Ltd.
- Ivax Pharmaceuticals
- Mead Johnson and Co.
- Pharmachemie BV
- Pliva Inc.
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
Dosage forms
Form | Route | Strength |
---|---|---|
Injection, powder, lyophilized, for suspension | intravenous | 100 mg/20mL |
Powder for suspension | intravenous | 100 mg |
Injection | intravenous | 100 mg/16.7mL |
Injection | intravenous | 30 mg/5mL |
Injection | intravenous | 300 mg/50mL |
Injection | intravenous | 6 mg/mL |
Injection, solution | intravenous | 6 mg/mL |
Injection, solution, concentrate | intravenous | 6 mg/mL |
Solution | intravenous | 6 mg |
Liquid | intravenous | 6 mg |
Form | Route | Strength |
---|---|---|
Injection, powder, lyophilized, for suspension | intravenous | 100 mg/20mL |
Powder for suspension | intravenous | 100 mg |
Injection | intravenous | 100 mg/16.7mL |
Injection | intravenous | 30 mg/5mL |
Injection | intravenous | 300 mg/50mL |
Injection | intravenous | 6 mg/mL |
Injection, solution | intravenous | 6 mg/mL |
Injection, solution, concentrate | intravenous | 6 mg/mL |
Solution | intravenous | 6 mg |
Liquid | intravenous | 6 mg |
Prices
Unit description | Cost | Unit |
---|---|---|
Paclitaxel 150 mg/25 ml vial | $3.36 | ml |
Paclitaxel 30 mg/5 ml vial | $3.54 | ml |
Paclitaxel 100 mg/16.7 ml vial | $4.45 | ml |
Paclitaxel 300 mg/50 ml vial | $5.31 | ml |
Onxol 30 mg/5 ml vial | $34.54 | ml |
Onxol 300 mg/50 ml vial | $34.54 | ml |
Taxol 30 mg/5 ml vial | $35.06 | ml |
Abraxane 100 mg vial | $1119.6 | vial |
Unit description | Cost | Unit |
---|---|---|
Paclitaxel 150 mg/25 ml vial | $3.36 | ml |
Paclitaxel 30 mg/5 ml vial | $3.54 | ml |
Paclitaxel 100 mg/16.7 ml vial | $4.45 | ml |
Paclitaxel 300 mg/50 ml vial | $5.31 | ml |
Onxol 30 mg/5 ml vial | $34.54 | ml |
Onxol 300 mg/50 ml vial | $34.54 | ml |
Taxol 30 mg/5 ml vial | $35.06 | ml |
Abraxane 100 mg vial | $1119.6 | vial |
Patents
Country | Patent Number | Approved | Expires (estimated) |
---|---|---|---|
2086874 | Canada | 1998-09-01 | 2013-01-07 |
2155947 | Canada | 2007-08-21 | 2014-02-22 |
5439686 | United States | 1993-02-22 | 2013-02-22 |
5498421 | United States | 1993-03-12 | 2013-03-12 |
Interactions
Drug | Interaction |
---|---|
Abiraterone | The serum concentration of Paclitaxel can be increased when it is combined with Abiraterone. |
Aprepitant | The serum concentration of Paclitaxel can be increased when it is combined with Aprepitant. |
Aripiprazole | The serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel. |
Atazanavir | The serum concentration of Paclitaxel can be increased when it is combined with Atazanavir. |
Bexarotene | The serum concentration of Bexarotene can be increased when it is combined with Paclitaxel. |
Bosentan | The serum concentration of Paclitaxel can be decreased when it is combined with Bosentan. |
Carboplatin | Carboplatin may increase the myelosuppressive activities of Paclitaxel. |
Cisplatin | Cisplatin may increase the myelosuppressive activities of Paclitaxel. |
Clozapine | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine. |
Conivaptan | The serum concentration of Paclitaxel can be increased when it is combined with Conivaptan. |
Dabrafenib | The serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib. |
Dasatinib | The serum concentration of Paclitaxel can be increased when it is combined with Dasatinib. |
Daunorubicin | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Daunorubicin. |
Deferasirox | The serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox. |
Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel. |
Doxorubicin | The metabolism of Doxorubicin can be decreased when combined with Paclitaxel. |
Epirubicin | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Epirubicin. |
Fluconazole | The metabolism of Paclitaxel can be decreased when combined with Fluconazole. |
Fosaprepitant | The serum concentration of Paclitaxel can be increased when it is combined with Fosaprepitant. |
Fusidic Acid | The serum concentration of Paclitaxel can be increased when it is combined with Fusidic Acid. |
Hydrocodone | The serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel. |
Idarubicin | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin. |
Idelalisib | The serum concentration of Paclitaxel can be increased when it is combined with Idelalisib. |
Ivacaftor | The serum concentration of Paclitaxel can be increased when it is combined with Ivacaftor. |
Leflunomide | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide. |
Luliconazole | The serum concentration of Paclitaxel can be increased when it is combined with Luliconazole. |
Metamizole | The risk or severity of adverse effects can be increased when Metamizole is combined with Paclitaxel. |
Mifepristone | The serum concentration of Paclitaxel can be increased when it is combined with Mifepristone. |
Mitotane | The serum concentration of Paclitaxel can be decreased when it is combined with Mitotane. |
Mitoxantrone | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoxantrone. |
Natalizumab | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab. |
Nelfinavir | The metabolism of Paclitaxel can be decreased when combined with Nelfinavir. |
Netupitant | The serum concentration of Paclitaxel can be increased when it is combined with Netupitant. |
Nimodipine | The serum concentration of Nimodipine can be decreased when it is combined with Paclitaxel. |
Oxaliplatin | Oxaliplatin may increase the myelosuppressive activities of Paclitaxel. |
Palbociclib | The serum concentration of Paclitaxel can be increased when it is combined with Palbociclib. |
Phenytoin | The metabolism of Paclitaxel can be increased when combined with Phenytoin. |
Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel. |
Ranolazine | The serum concentration of Paclitaxel can be increased when it is combined with Ranolazine. |
Ritonavir | The metabolism of Paclitaxel can be decreased when combined with Ritonavir. |
Roflumilast | Roflumilast may increase the immunosuppressive activities of Paclitaxel. |
Rosiglitazone | The metabolism of Paclitaxel can be decreased when combined with Rosiglitazone. |
Saquinavir | The serum concentration of Paclitaxel can be increased when it is combined with Saquinavir. |
Saxagliptin | The serum concentration of Saxagliptin can be decreased when it is combined with Paclitaxel. |
Siltuximab | The serum concentration of Paclitaxel can be decreased when it is combined with Siltuximab. |
Simeprevir | The serum concentration of Paclitaxel can be increased when it is combined with Simeprevir. |
Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel. |
Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel. |
St. John's Wort | The serum concentration of Paclitaxel can be decreased when it is combined with St. John's Wort. |
Stiripentol | The serum concentration of Paclitaxel can be increased when it is combined with Stiripentol. |
Tacrolimus | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel. |
Tesmilifene | The serum concentration of Paclitaxel can be decreased when it is combined with Tesmilifene. |
Tocilizumab | The serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab. |
Tofacitinib | Paclitaxel may increase the immunosuppressive activities of Tofacitinib. |
Trastuzumab | The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab. |
Trimethoprim | The metabolism of Paclitaxel can be decreased when combined with Trimethoprim. |
Verapamil | The serum concentration of Paclitaxel can be increased when it is combined with Verapamil. |
Vinorelbine | Paclitaxel may increase the neurotoxic activities of Vinorelbine. |
Drug | Interaction |
---|---|
Abiraterone | The serum concentration of Paclitaxel can be increased when it is combined with Abiraterone. |
Aprepitant | The serum concentration of Paclitaxel can be increased when it is combined with Aprepitant. |
Aripiprazole | The serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel. |
Atazanavir | The serum concentration of Paclitaxel can be increased when it is combined with Atazanavir. |
Bexarotene | The serum concentration of Bexarotene can be increased when it is combined with Paclitaxel. |
Bosentan | The serum concentration of Paclitaxel can be decreased when it is combined with Bosentan. |
Carboplatin | Carboplatin may increase the myelosuppressive activities of Paclitaxel. |
Cisplatin | Cisplatin may increase the myelosuppressive activities of Paclitaxel. |
Clozapine | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine. |
Conivaptan | The serum concentration of Paclitaxel can be increased when it is combined with Conivaptan. |
Dabrafenib | The serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib. |
Dasatinib | The serum concentration of Paclitaxel can be increased when it is combined with Dasatinib. |
Daunorubicin | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Daunorubicin. |
Deferasirox | The serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox. |
Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel. |
Doxorubicin | The metabolism of Doxorubicin can be decreased when combined with Paclitaxel. |
Epirubicin | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Epirubicin. |
Fluconazole | The metabolism of Paclitaxel can be decreased when combined with Fluconazole. |
Fosaprepitant | The serum concentration of Paclitaxel can be increased when it is combined with Fosaprepitant. |
Fusidic Acid | The serum concentration of Paclitaxel can be increased when it is combined with Fusidic Acid. |
Hydrocodone | The serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel. |
Idarubicin | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin. |
Idelalisib | The serum concentration of Paclitaxel can be increased when it is combined with Idelalisib. |
Ivacaftor | The serum concentration of Paclitaxel can be increased when it is combined with Ivacaftor. |
Leflunomide | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide. |
Luliconazole | The serum concentration of Paclitaxel can be increased when it is combined with Luliconazole. |
Metamizole | The risk or severity of adverse effects can be increased when Metamizole is combined with Paclitaxel. |
Mifepristone | The serum concentration of Paclitaxel can be increased when it is combined with Mifepristone. |
Mitotane | The serum concentration of Paclitaxel can be decreased when it is combined with Mitotane. |
Mitoxantrone | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoxantrone. |
Natalizumab | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab. |
Nelfinavir | The metabolism of Paclitaxel can be decreased when combined with Nelfinavir. |
Netupitant | The serum concentration of Paclitaxel can be increased when it is combined with Netupitant. |
Nimodipine | The serum concentration of Nimodipine can be decreased when it is combined with Paclitaxel. |
Oxaliplatin | Oxaliplatin may increase the myelosuppressive activities of Paclitaxel. |
Palbociclib | The serum concentration of Paclitaxel can be increased when it is combined with Palbociclib. |
Phenytoin | The metabolism of Paclitaxel can be increased when combined with Phenytoin. |
Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel. |
Ranolazine | The serum concentration of Paclitaxel can be increased when it is combined with Ranolazine. |
Ritonavir | The metabolism of Paclitaxel can be decreased when combined with Ritonavir. |
Roflumilast | Roflumilast may increase the immunosuppressive activities of Paclitaxel. |
Rosiglitazone | The metabolism of Paclitaxel can be decreased when combined with Rosiglitazone. |
Saquinavir | The serum concentration of Paclitaxel can be increased when it is combined with Saquinavir. |
Saxagliptin | The serum concentration of Saxagliptin can be decreased when it is combined with Paclitaxel. |
Siltuximab | The serum concentration of Paclitaxel can be decreased when it is combined with Siltuximab. |
Simeprevir | The serum concentration of Paclitaxel can be increased when it is combined with Simeprevir. |
Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel. |
Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel. |
St. John's Wort | The serum concentration of Paclitaxel can be decreased when it is combined with St. John's Wort. |
Stiripentol | The serum concentration of Paclitaxel can be increased when it is combined with Stiripentol. |
Tacrolimus | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel. |
Tesmilifene | The serum concentration of Paclitaxel can be decreased when it is combined with Tesmilifene. |
Tocilizumab | The serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab. |
Tofacitinib | Paclitaxel may increase the immunosuppressive activities of Tofacitinib. |
Trastuzumab | The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab. |
Trimethoprim | The metabolism of Paclitaxel can be decreased when combined with Trimethoprim. |
Verapamil | The serum concentration of Paclitaxel can be increased when it is combined with Verapamil. |
Vinorelbine | Paclitaxel may increase the neurotoxic activities of Vinorelbine. |
Food Interactions:
- Avoid echinacea.
- Avoid grapefruit and grapefruit juice due to potential increase of paclitaxel.
Taxonomy
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Acetate salts
- Alpha-acyloxy ketones
- Benzoic acid esters
- Benzoyl derivatives
- Benzylethers
- Beta amino acids and derivatives
- Carboxylic acid esters
- Cyclic alcohols and derivatives
- Dialkyl ethers
- Dicarboxylic acids and derivatives
- Fatty acid esters
- Hydrocarbon derivatives
- Ketones
- Monosaccharides
- N-benzylbenzamides
- Organonitrogen compounds
- Oxacyclic compounds
- Oxetanes
- Phenylpropylamines
- Secondary alcohols
- Secondary carboxylic acid amides
- Tertiary alcohols
substituent:
- Acetate salt
- Alcohol
- Alpha-acyloxy ketone
- Aromatic heteropolycyclic compound
- Benzamide
- Benzenoid
- Benzoate ester
- Benzoic acid or derivatives
- Benzoyl
- Benzylether
- Beta amino acid or derivatives
- Carbonyl group
- Carboxamide group
- Carboxylic acid derivative
- Carboxylic acid ester
- Cyclic alcohol
- Dialkyl ether
- Dicarboxylic acid or derivatives
- Ether
- Fatty acid ester
- Fatty acyl
- Hydrocarbon derivative
- Ketone
- Monocyclic benzene moiety
- Monosaccharide
- N-benzylbenzamide
- Organoheterocyclic compound
- Organonitrogen compound
- Organooxygen compound
- Oxacycle
- Oxetane
- Phenylpropylamine
- Secondary alcohol
- Secondary carboxylic acid amide
- Taxane diterpenoid
- Tertiary alcohol
References
General Reference: # Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995 Feb 15;55(4):753-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7850785 # Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5553076 # Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978 Aug;62(8):1219-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/688258 # Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7603142 # ABI 007. Drugs R D. 2004;5(3):155-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15139776 # Gaitanis A, Staal S: Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 2010;624:385-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20217610
External Links:
Resource | Link |
---|---|
RxList | http://www.rxlist.com/cgi/generic/paclitaxel.htm |
Drugs.com | http://www.drugs.com/cdi/paclitaxel.html |
Resource | Link |
---|---|
RxList | http://www.rxlist.com/cgi/generic/paclitaxel.htm |
Drugs.com | http://www.drugs.com/cdi/paclitaxel.html |
ATC Codes:
- Array
AHFS Codes:
- 10:00.00
MSDS: Download